コーパス検索結果 (１語後でソート)
通し番号をクリックするとPubMedの該当ページを表示します
1 ait (for example, rs7115089, miR-125b-5p and high-density lipoprotein cholesterol).
2 s of low-density lipoprotein cholesterol and high-density lipoprotein cholesterol.
3 density lipoprotein cholesterol families) or high-density lipoprotein cholesterol.
4 n part owing to hypertriglyceridemia and low high-density lipoprotein cholesterol.
5 ociated with TGs, total cholesterol, and non-high-density lipoprotein cholesterol.
6 f low-density lipoprotein cholesterol or non-high-density lipoprotein cholesterol.
7 (LOF) mutations in LIPG in individuals with high-density lipoprotein cholesterol.
8 may preferentially improve triglycerides and high-density lipoprotein cholesterol.
9 tolic blood pressure, total cholesterol, and high-density lipoprotein cholesterol.
10 retic peptide levels, physical activity, and high-density lipoprotein cholesterol.
11 the LDL fractions, concomitant with elevated high-density lipoprotein cholesterol.
12 h diabetes with hypertriglyceridemia and low high-density lipoprotein cholesterol.
13 cholesterol and triglyceride, and increasing high-density lipoprotein cholesterol.
14 effect estimate as large as that of total or high-density lipoprotein cholesterol.
15 ol, low-density lipoprotein-cholesterol, and high-density lipoprotein-cholesterol.
16 ted QT interval, HR-corrected QT interval or high-density lipoprotein-cholesterol.
17 (0.77 mg/dL; 95% CI, 0.18-1.36; P=0.01) and high-density lipoprotein cholesterol (0.42 mg/dL; 95% CI
18 s of low-density lipoprotein cholesterol and high-density lipoprotein cholesterol (0.97+/-0.16 and 0.
19 triglycerides, but was associated with lower high density lipoprotein cholesterol (-0.014 standard de
20 (0.70 mmHg; 95% CI = 0.24-1.16) and reduced high-density lipoprotein cholesterol (-0.02 mmol/l; 95%
21 lesterol [-0.01 mmol/l, p = 0.83]; increased high-density lipoprotein cholesterol [0.06 mmol/l, p = 0
22 lesterol (1.6 [1.1-2.1]), and borderline low high-density lipoprotein cholesterol (1.4 [1.0-1.8]) rem
23 ), and combined hypertension, LDL-C, and non-high-density lipoprotein cholesterol (1.8% [95% CI, 0.4%
24 lipoprotein cholesterol (27.9 to 60.0%), non-high-density lipoprotein cholesterol (10.0 to 36.6%), ap
25 traits within a locus (12 out of 33 loci for high-density lipoprotein cholesterol, 10 of 35 loci for
26 und in 8.6% for total cholesterol, 22.5% for high-density lipoprotein-cholesterol, 12.0% for non-high
27 mL), higher mean fasting serum levels of non-high-density lipoprotein cholesterol (126.5 and 121.1 mg
28 statistically significantly increased serum high-density lipoprotein cholesterol (13 trials; net cha
29 7 (low-density lipoprotein cholesterol), 8 (high-density lipoprotein cholesterol), 14 (triglycerides
30 showed nominal significant association with high-density lipoprotein cholesterol (2 SNPs), low-densi
31 ion led to greater improvements in levels of high-density lipoprotein cholesterol (3.86 mg/dL [to con
32 rol, 109.23 mg/dL (103.68-114.79 mg/dL); for high-density lipoprotein cholesterol, 42.80 mg/dL (39.84
33 respectively; P<0.0001) and higher levels of high-density lipoprotein cholesterol (45 +/- 12 mg/dL ve
34 .4% smaller waist circumference, 4.4% higher high-density lipoprotein cholesterol, 8.5% lower triglyc
35 nsity lipoprotein-cholesterol, 12.0% for non-high-density lipoprotein-cholesterol, 8.0% for low-densi
36 le decrease of -7.35 mg/dL (-0.19 mmol/L) in high-density lipoprotein cholesterol (95% CI, -3.09 to -
37 high-density lipoprotein cholesterol, or non-high-density lipoprotein cholesterol, although triglycer
38 e aminotransferase, triglycerides, and lower high-density lipoprotein cholesterol and adiponectin lev
39 ed for LDL-C were observed with achieved non-high-density lipoprotein cholesterol and apolipoprotein
40 in enhancers (the strongest effects were for high-density lipoprotein cholesterol and body mass index
41 t association was found for higher levels of high-density lipoprotein cholesterol and decreased preva
42 nonfasting glucose levels; however, reduced high-density lipoprotein cholesterol and elevated C-reac
43 adjusted models, women had higher levels of high-density lipoprotein cholesterol and high-density li
44 cational attainment, exercise, levels of non-high-density lipoprotein cholesterol and high-sensitivit
45 ovariates, no associations of serum total or high-density lipoprotein cholesterol and incident prolif
46 amino acid metabolites tied to low levels of high-density lipoprotein cholesterol and insulin resista
47 e MetS components and CA, except for reduced high-density lipoprotein cholesterol and nonfasting gluc
48 no associations, or inverse associations of high-density lipoprotein cholesterol and total cholester
49 oprotein cholesterol, and ratios of total to high-density lipoprotein cholesterol and triglycerides t
50 -binding globulin), markers of dyslipidemia (high-density lipoprotein cholesterol and triglycerides),
51 ssociated with CVD risk after adjustment for high-density lipoprotein-cholesterol and did not provide
52 evels with body mass index, particularly for high-density lipoprotein-cholesterol and triglycerides (
53 d alcohol and was positively associated with high-density-lipoprotein cholesterol and intakes of poly
55 erol, 71 single-nucleotide polymorphisms for high-density lipoprotein cholesterol, and 40 single-nucl
56 olesterol, the ratio of total cholesterol to high-density lipoprotein cholesterol, and 8-OHdG levels.
57 e relationship between additional LDL-C, non-high-density lipoprotein cholesterol, and apolipoprotein
58 r age, sex, hypertension, smoking, diabetes, high-density lipoprotein cholesterol, and body mass inde
59 c biomarkers, including glycated hemoglobin, high-density lipoprotein cholesterol, and C-reactive pro
60 diastolic blood pressure, total cholesterol, high-density lipoprotein cholesterol, and glucose levels
61 lic abnormalities (high fasting glucose, low high-density lipoprotein cholesterol, and high triglycer
62 Low-density lipoprotein cholesterol, non-high-density lipoprotein cholesterol, and ratios of tota
63 ia, neuroticism, educational attainment, and high-density lipoprotein cholesterol, and significant ne
64 mean concentrations of total cholesterol and high-density lipoprotein cholesterol, and smoking status
65 index, low-density lipoprotein cholesterol, high-density lipoprotein cholesterol, and tobacco use.
68 r disease, circulating levels of fibrinogen, high-density lipoprotein cholesterol, and uric acid), we
70 ity lipoprotein cholesterol; lower levels of high-density lipoprotein cholesterol; and, to a lesser e
73 were also observed in total cholesterol, non-high-density lipoprotein cholesterol, apolipoprotein B,
74 terol; lipoprotein(a), apolipoprotein B, and high-density lipoprotein cholesterol are largely unaffec
75 for other cardiac risk factors including non-high-density lipoprotein cholesterol at 55 years of age
76 nce, blood pressure, triglycerides, glucose, high-density lipoprotein cholesterol) at 15 (n=512), 16
77 e saw a small increase in rate of change for high-density lipoprotein cholesterol (beta = 0.28 mg/dL;
78 associated in opposite directions with both high-density lipoprotein cholesterol (beta coefficient=-
79 ension, family history of MI, smoking, total/high-density lipoprotein cholesterol, body mass index, a
81 ocardial infarction, smoking, serum low- and high-density lipoprotein cholesterol, C-reactive protein
82 ding hypertension, hypertriglyceridemia, low high-density lipoprotein cholesterol, central obesity, a
83 re, body mass index, apolipoprotein A-1, and high-density lipoprotein cholesterol concentration (beta
84 ted fasting blood glucose concentration, low high-density lipoprotein cholesterol concentration, hype
86 rapy, body mass index, heart rate, total and high-density lipoprotein cholesterol concentrations, smo
88 ith concomitant hypertension, LDL-C, and non-high-density lipoprotein cholesterol control (odds ratio
89 chemic heart disease, stroke, smoking, serum high-density lipoprotein cholesterol, creatinine, glucos
90 markers: fasting glucose, total cholesterol, high-density lipoprotein cholesterol, dehydroepiandroste
92 .6) and 2.5 mm Hg (95% CI, 1.7-3.3), and for high-density lipoprotein cholesterol, differences were -
94 -regression for various covariates including high-density lipoprotein cholesterol, each 1 unit of nat
95 carriers, carriers of PTV at CETP had higher high-density lipoprotein cholesterol (effect size, 22.6
96 pectroscopy and a validated ex vivo assay of high-density lipoprotein cholesterol efflux capacity.
97 ssure, ratio of fasting total cholesterol to high-density lipoprotein cholesterol, estimated glomerul
98 ty groups had an increased prevalence of low high-density lipoprotein cholesterol, except for Japanes
99 aboratory value >/=150 mg/dL), low levels of high-density lipoprotein cholesterol (fasting laboratory
100 abolic biomarkers (diastolic blood pressure, high-density lipoprotein cholesterol, fasting and 2-hour
102 de association studies (from 3.6 to 7.6% for high-density lipoprotein cholesterol, from 5.0 to 8.8% f
103 were used: hypertension, diabetes, total and high density lipoprotein cholesterol, glycated haemoglob
104 low-density lipoprotein cholesterol and non-high-density lipoprotein cholesterol goals in secondary
106 een duration of moderate hyperlipidemia (non-high-density lipoprotein cholesterol >/= 160 mg/dL) in e
107 oprotein cholesterol (LDL-C) <160 mg/dl, and high-density lipoprotein cholesterol >/=40 mg/dl.
108 w-density lipoprotein cholesterol <85 mg/dl, high-density lipoprotein cholesterol >40 mg/dl, and trig
110 exposure to even moderate elevations in non-high-density lipoprotein cholesterol have elevated risk
113 ively polar CETP inhibitor 26 showing robust high density lipoprotein-cholesterol (HDL-C) elevation a
114 nfidence interval (CI): 3.9, 17.9] and lower high-density lipoprotein cholesterol (HDL) (-1.9 mg/dL;
115 ded the triple goals of LDL-C <70 mg/dl, non-high-density lipoprotein cholesterol (HDL-C) <100 mg/dl,
116 s of total cholesterol (TC) (>/= 200 mg/dL), high-density lipoprotein cholesterol (HDL-C) (<40 mg/dL)
117 acylglycerols (TAG) (p = 3.18 x 10(-42)) and high-density lipoprotein cholesterol (HDL-C) (p = 1.35 x
118 rs have been shown to substantially increase high-density lipoprotein cholesterol (HDL-C) and apolipo
119 rdance between population percentiles of non-high-density lipoprotein cholesterol (HDL-C) and low-den
120 LDL-C by 30-40% as well as raising levels of high-density lipoprotein cholesterol (HDL-C) and may als
121 Although the inverse association between high-density lipoprotein cholesterol (HDL-C) and risk of
123 y artery disease (CAD), but the relevance of high-density lipoprotein cholesterol (HDL-C) and triglyc
126 ipoprotein cholesterol (LDL-C) and increased high-density lipoprotein cholesterol (HDL-C) compared wi
127 LDL-c from 155 to 128 mg/dL (P < .001), and high-density lipoprotein cholesterol (HDL-c) from 50.3 t
128 ational epidemiologic studies, higher plasma high-density lipoprotein cholesterol (HDL-C) has been as
129 terventions targeting triglycerides (TGs) or high-density lipoprotein cholesterol (HDL-C) have produc
130 cause of ischemic stroke, and a low level of high-density lipoprotein cholesterol (HDL-C) is also con
132 diet only), red wine significantly increased high-density lipoprotein cholesterol (HDL-C) level by 0.
134 ubfamily A, member 1 (ABCA1) and circulating high-density lipoprotein cholesterol (HDL-C) levels in v
135 patients with established CV disease and low high-density lipoprotein cholesterol (HDL-C) levels, com
136 model accounting for effects on LDL-C and/or high-density lipoprotein cholesterol (HDL-C) levels, the
138 B type 1 (SCARB1) plays an important role in high-density lipoprotein cholesterol (HDL-C) metabolism
140 % of children aged 9-11 years had either low high-density lipoprotein cholesterol (HDL-C) or high non
141 mean triglyceride levels increased but mean high-density lipoprotein cholesterol (HDL-C) remained un
142 -density lipoprotein cholesterol (LDL-C) and high-density lipoprotein cholesterol (HDL-C) were either
143 al difference (mg/dL) per 1 SD was -1.89 for high-density lipoprotein cholesterol (HDL-C), 9.5 for lo
144 d these variants for association with LDL-C, high-density lipoprotein cholesterol (HDL-C), and trigly
145 low-density lipoprotein-cholesterol (LDL-C), high-density lipoprotein cholesterol (HDL-C), and trigly
146 low-density lipoprotein cholesterol (LDL-C), high-density lipoprotein cholesterol (HDL-C), and trigly
148 poraneously assayed total serum cholesterol, high-density lipoprotein cholesterol (HDL-C), low-densit
149 preeclampsia and maternal total cholesterol, high-density lipoprotein cholesterol (HDL-C), low-densit
151 ol levels, including total cholesterol (TC), high-density lipoprotein cholesterol (HDL-C), low-densit
159 density lipoprotein cholesterol (non-HDL-C), high-density lipoprotein cholesterol (HDL-C); and among
160 vels of TRAP, was positively associated with high-density lipoprotein cholesterol (HDL-C; beta = 8.36
161 ated locus associated with triglycerides and high-density lipoprotein cholesterol (HDL-C; cg27243685;
162 m Hg; 4) triglycerides >/= 150 mg/dl; and 5) high-density lipoprotein-cholesterol (HDL-C) <40 mg/dl (
163 sought to evaluate the vascular risk of low high-density lipoprotein-cholesterol (HDL-C) in relation
164 y sought to assess the independent effect of high-density lipoprotein-cholesterol (HDL-C) level on ca
165 tive epidemiological studies have shown that high-density lipoprotein-cholesterol (HDL-C) levels are
166 ociations of triglyceride, total cholesterol/high-density lipoprotein-cholesterol (HDL-C) ratio, HDL-
168 ntly associated with total cholesterol (TC), high-density-lipoprotein cholesterol (HDL-C), low-densit
169 low-density lipoprotein cholesterol [LDL-C], high-density lipoprotein cholesterol [HDL-C], and trigly
170 asting lipid fractions (triglycerides [TGs], high-density lipoprotein cholesterol [HDL-C], low-densit
171 ores (GRSs) for four blood lipid phenotypes (high-density lipoprotein cholesterol [HDL-c], low-densit
172 nterestingly, significantly higher levels of high density lipoprotein cholesterol (HDLc) were observe
175 dominal obesity, elevated triglycerides, low high-density lipoprotein cholesterol, high blood pressur
176 high blood pressure, high triglycerides, low high-density lipoprotein cholesterol, high C-reactive pr
178 e rs58542926 variant was not associated with high-density lipoprotein cholesterol in a large sample (
179 ansaminase, white blood cell count and lower high-density lipoprotein cholesterol in men, and with hi
180 sure, and triglyceride levels, decreased and high-density lipoprotein cholesterol increased more afte
181 lesterol (decreased in LFHC group only), and high-density lipoprotein cholesterol (increased in VHFLC
183 on between nuts and hypertriglyceridemia and high-density lipoprotein cholesterol is not well establi
184 25(OH)D levels, whereas genetically reduced high-density lipoprotein-cholesterol is not associated w
185 L cholesterol and lipoprotein (a) and raises high-density lipoprotein cholesterol, it has adverse eff
186 ity lipoprotein cholesterol level <70 mg/dL, high-density lipoprotein cholesterol level >50 mg/dL [wo
187 ), triglyceride level (-40%, -29%, and -8%), high-density lipoprotein cholesterol level (32%, 30%, an
189 oded by the CNR1 gene--is known to influence high-density lipoprotein cholesterol level as well, huma
190 By testing each variant for association with high-density lipoprotein cholesterol level in a clinical
191 sion, thereby linking CNR1 gene variation to high-density lipoprotein cholesterol level in humans.
192 f at least 70 mg/dL or a final screening non-high-density lipoprotein cholesterol level of at least 1
193 ity, higher systolic blood pressure, a lower high-density lipoprotein cholesterol level, a higher tri
194 physical activity, total cholesterol level, high-density lipoprotein cholesterol level, systolic blo
197 e, estimated glomerular filtration rate, and high density lipoprotein cholesterol levels were inverse
198 20%; p = 0.004), and have lower on-treatment high-density lipoprotein cholesterol levels (48 +/- 16 m
199 .7 versus 134.6 to 141.3 mg/dL), >20% higher high-density lipoprotein cholesterol levels (geometric m
200 ted with an increase in both low-density and high-density lipoprotein cholesterol levels and with red
201 ice lacking T39 (T39(-/-)) display increased high-density lipoprotein cholesterol levels associated w
202 ion carriers had significantly higher plasma high-density lipoprotein cholesterol levels compared wit
204 il counts decreased, hemoglobin and low- and high-density lipoprotein cholesterol levels increased, a
205 iglyceride levels greater than 204 mg/dL and high-density lipoprotein cholesterol levels less than 34
206 Cystatin C levels were positively and plasma high-density lipoprotein cholesterol levels negatively a
209 s were also more likely to smoke, have lower high-density lipoprotein cholesterol levels, and have hi
210 rglycemia, elevated triglyceride levels, low high-density lipoprotein cholesterol levels, high blood
211 s in total, low-density lipoprotein, and non-high-density lipoprotein cholesterol levels, in triglyce
212 essure, treatment of hypertension, total and high-density lipoprotein cholesterol levels, smoking, an
213 djusting for age, race, sex, low-density and high-density lipoprotein cholesterol levels, triglycerid
218 ations, low-density lipoprotein cholesterol, high-density lipoprotein cholesterol, lipid-lowering med
219 ntly reduced levels of apolipoprotein B, non-high-density lipoprotein cholesterol, lipoprotein(a), an
220 ent for low-density lipoprotein cholesterol, high-density lipoprotein cholesterol, lipoprotein(a), tr
221 or remnant cholesterol, and -8 mg/dl for non-high-density lipoprotein cholesterol; lipoprotein(a), ap
223 -wide DNA methylation and blood lipid levels high-density lipoprotein cholesterol, low-density lipopr
224 bilirubin, total cholesterol, triglycerides, high-density lipoprotein cholesterol, low-density lipopr
225 sing data set quartiles of total cholesterol/high-density lipoprotein cholesterol, low-density lipopr
226 index, body fat percentage, lean body mass, high-density lipoprotein cholesterol, low-density lipopr
227 adjustment for age, body mass index, gender, high-density lipoprotein cholesterol, low-density lipopr
228 m levels of triglyceride, total cholesterol, high-density lipoprotein cholesterol, low-density lipopr
230 ture mapping analysis for total cholesterol, high-density lipoprotein cholesterol, low-density lipopr
231 e-mapping analysis that were associated with high-density lipoprotein cholesterol, low-density lipopr
232 rs, carriers of PTV at CETP displayed higher high-density lipoprotein cholesterol, lower low-density
233 s of total, low-density lipoprotein, and non-high-density lipoprotein cholesterol; lower levels of hi
234 ein cholesterol >/= 3.36 mmol/L (130 mg/dL), high-density lipoprotein cholesterol <1.03 mmol/L (40 mg
235 events and control of 6 RFs (no smoking, non-high-density lipoprotein cholesterol <130 mg/dl, triglyc
236 95% CI: 0.05, 0.19 mmol/L; P = 0.0001), and high-density lipoprotein cholesterol (MD: 0.02 mmol/L; 9
237 methodology to a real data set consisting of high-density lipoprotein cholesterol measurements in mic
238 es (n=7603; beta=-71.20; P=0.007) and higher high-density lipoprotein cholesterol (n=8891; beta=15.65
240 cholesterol (LDL-C), triglycerides, and non-high-density lipoprotein cholesterol (non-HDL-C) present
241 t also LDL-related biomarkers, including non-high-density lipoprotein cholesterol (non-HDL-C), apolip
243 uths, mean serum total cholesterol (TC), non-high-density lipoprotein cholesterol (non-HDL-C), high-d
244 density lipoprotein cholesterol (LDL-C), non-high-density lipoprotein cholesterol (non-HDL-C), or apo
245 elated to on-treatment apolipoprotein B, non-high-density lipoprotein cholesterol (non-HDL-C), trigyl
247 38 mg/dL (-28%, P = 0.016) and increases in high density lipoprotein-cholesterol of 5 mg/dL (15%; P
248 ompared with controls, despite no changes in high-density lipoprotein cholesterol or other circulatin
249 sterol, low-density lipoprotein cholesterol, high-density lipoprotein cholesterol or triglycerides we
250 ith >/= 5 births had the highest odds of low high-density lipoprotein cholesterol (OR, 1.5; 95% confi
251 ol, low-density lipoprotein cholesterol, non-high-density lipoprotein cholesterol, or low-density lip
252 een for low-density lipoprotein cholesterol, high-density lipoprotein cholesterol, or non-high-densit
253 ences were found for fasting plasma glucose, high-density lipoprotein cholesterol, or triglycerides w
254 sterol, low-density lipoprotein-cholesterol, high-density lipoprotein-cholesterol, or triglyceride, 4
255 lipoprotein cholesterol, and HbA1c and lower high-density lipoprotein cholesterol (P < 0.001 for all)
256 sex (p = 0.02), body mass index (p = 0.01), high-density lipoprotein cholesterol (p = 0.005), N-term
257 sedentary time was associated with decreased high-density lipoprotein cholesterol (P=0.04), and incre
258 leukin-10 remained persistently elevated and high-density lipoprotein cholesterol persistently depres
259 epatitis A), biochemical (e.g., carotenoids, high-density lipoprotein cholesterol), physiological (e.
260 lood pressure, suboptimal triglycerides, and high-density lipoprotein-cholesterol prevalence have cor
261 largely explained by lowering of non-HDL-C (high-density lipoprotein cholesterol), rather than incre
262 -11.3% and -13.6%), and total cholesterol to high-density lipoprotein cholesterol ratio (-5.6% and -8
263 h ARIC metabolic phenotypes, including total:high-density lipoprotein cholesterol ratio (rG=-0.44, P=
264 vents, digoxin use, and total cholesterol to high-density lipoprotein cholesterol ratio were associat
265 ded risk factors were body mass index, total:high-density lipoprotein cholesterol ratio, and systolic
267 lin resistance), serum-triglyceride-to-serum-high-density lipoprotein-cholesterol ratio TG/HDL-C, or
268 ociations were also identified (eg, total-to-high-density-lipoprotein cholesterol ratio: b = -0.22 pe
269 and years of schooling (rG=0.18, s.e.=0.03), high-density lipoprotein cholesterol (rG=0.28, s.e.=0.05
270 CI, 1.11-1.94]), an elevated serum level of high-density lipoprotein cholesterol (RR per 1-SD increa
271 y >/=2 hours per day (RR 0.69; P=0.002), and high-density lipoprotein cholesterol (RR per SD 0.80; P=
273 , sex, systolic blood pressure, cholesterol, high-density lipoprotein cholesterol, smoking, prevalent
274 ize, and in mouse models, elevated levels of high-density lipoprotein cholesterol suppress blood mono
275 s such as waist circumference, triglyceride, high-density lipoprotein cholesterol, systolic and diast
276 oking, diabetes mellitus, total cholesterol, high-density lipoprotein cholesterol, systolic blood pre
278 enzymatic activity and a 35% increase of the high density lipoprotein cholesterol that was observed u
279 gene, TEAD2, is found to be associated with high-density lipoprotein cholesterol through gene-based
281 cholesterol and TG profiles while improving high-density lipoprotein cholesterol to CHOL ratio in db
282 to decrease low-density lipoprotein and non-high-density lipoprotein cholesterol to specific target
283 physical activity, smoking, alcohol intake, high-density lipoprotein-cholesterol, total cholesterol,
284 ased fatty liver index (FLI)], dyslipidemia (high-density lipoprotein cholesterol, triglycerides), in
286 and fasting blood sample (total cholesterol, high-density lipoprotein cholesterol, triglycerides, glu
287 actors: low-density lipoprotein cholesterol, high-density lipoprotein cholesterol, triglycerides, typ
288 ypes of MDD with changes of fasting glucose, high-density lipoprotein-cholesterol, triglycerides, sys
289 notypes: V(G)/V(p)=31.4%, P<3.1x10(-11)) and high-density lipoprotein cholesterol (V(G)/V(p)=26.4%, P
290 ity lipoprotein cholesterol (LDL-C), and non-high-density lipoprotein cholesterol; values below diagn
291 rable objective biomarkers (concentration of high-density lipoprotein cholesterol, vitamin D and C-re
292 than in WT mice (2.6 versus 0.4 mmol/L), and high-density lipoprotein cholesterol was significantly l
294 lipoprotein cholesterol and triglycerides to high-density lipoprotein cholesterol were calculated.
295 us, smoking, higher triglycerides, and lower high-density lipoprotein cholesterol were more prevalent
296 s with CV disease and low baseline levels of high-density lipoprotein cholesterol were randomized to
297 tion between CCR2 and CX3CR1 expressions and high-density lipoprotein-cholesterol, whereas CCR5 expre
298 of higher systolic blood pressure and lower high-density lipoprotein cholesterol with Carotid artery
299 relationship of differences in on-treatment high-density lipoprotein cholesterol with the magnitude
300 t results were found for decreased levels of high-density lipoprotein cholesterol, with ORs of 2.97 (
WebLSDに未収録の専門用語（用法）は "新規対訳" から投稿できます。